Hematopoietic stem cell transplantation in juvenile myelomonocytic leukemia: analyse one centre experience and literature review

Allogeneic hematopoietic stem cell transplantation (HSCT) is the standard curative therapy for juvenile myelomonocytic leukemia (JMML). Seventeen patients with JMML received myeloablative conditioning (busulfan-based — 15, treosulfan-based — 2). Donors included 5 matched related siblings, 8 — matche...

Full description

Saved in:
Bibliographic Details
Main Authors: M. A. Maschan, L. A. Khachatryan, Yu. V. Skvortsova, E. E. Kurnikova, D. A. Shasheleva, V. O. Bobrynina, D. N. Balashov, E. V. Skorobogatova, D. D. Baydildina, G. A. Novichkova, A. A. Maschan
Format: Article
Language:Russian
Published: ABV-press 2014-07-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/105
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849409269306228736
author M. A. Maschan
L. A. Khachatryan
Yu. V. Skvortsova
E. E. Kurnikova
D. A. Shasheleva
V. O. Bobrynina
D. N. Balashov
E. V. Skorobogatova
D. D. Baydildina
G. A. Novichkova
A. A. Maschan
author_facet M. A. Maschan
L. A. Khachatryan
Yu. V. Skvortsova
E. E. Kurnikova
D. A. Shasheleva
V. O. Bobrynina
D. N. Balashov
E. V. Skorobogatova
D. D. Baydildina
G. A. Novichkova
A. A. Maschan
author_sort M. A. Maschan
collection DOAJ
description Allogeneic hematopoietic stem cell transplantation (HSCT) is the standard curative therapy for juvenile myelomonocytic leukemia (JMML). Seventeen patients with JMML received myeloablative conditioning (busulfan-based — 15, treosulfan-based — 2). Donors included 5 matched related siblings, 8 — matched unrelated volunteer or cord blood (2), 4 — mismatched relatives. Primary engraftment was achieved in 75 %. The rate of acute GVHD grade II–IV was 58 %, grade III–IV — 23 %. Chronic GVHD occurred in 33 % of patients. Five JMML relapses occurred. Relapse-free survival is 66 ± 12 %. Four patients died of transplant-related complications. TRM was 28 ± 12 %.Five patients died of disease progression. Overall survival is 38 ± 13 % with median follow-up of 13 months. A review of most important publications related to HSCT in JMML is provided.
format Article
id doaj-art-9bf29edc00a84e1c93d1e32f064b96fd
institution Kabale University
issn 1818-8346
2413-4023
language Russian
publishDate 2014-07-01
publisher ABV-press
record_format Article
series Онкогематология
spelling doaj-art-9bf29edc00a84e1c93d1e32f064b96fd2025-08-20T03:35:33ZrusABV-pressОнкогематология1818-83462413-40232014-07-0161455510.17650/1818-8346-2011-6-1-45-55120Hematopoietic stem cell transplantation in juvenile myelomonocytic leukemia: analyse one centre experience and literature reviewM. A. Maschan0L. A. Khachatryan1Yu. V. Skvortsova2E. E. Kurnikova3D. A. Shasheleva4V. O. Bobrynina5D. N. Balashov6E. V. Skorobogatova7D. D. Baydildina8G. A. Novichkova9A. A. Maschan10Federal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Children Clinical HospitalFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyAllogeneic hematopoietic stem cell transplantation (HSCT) is the standard curative therapy for juvenile myelomonocytic leukemia (JMML). Seventeen patients with JMML received myeloablative conditioning (busulfan-based — 15, treosulfan-based — 2). Donors included 5 matched related siblings, 8 — matched unrelated volunteer or cord blood (2), 4 — mismatched relatives. Primary engraftment was achieved in 75 %. The rate of acute GVHD grade II–IV was 58 %, grade III–IV — 23 %. Chronic GVHD occurred in 33 % of patients. Five JMML relapses occurred. Relapse-free survival is 66 ± 12 %. Four patients died of transplant-related complications. TRM was 28 ± 12 %.Five patients died of disease progression. Overall survival is 38 ± 13 % with median follow-up of 13 months. A review of most important publications related to HSCT in JMML is provided.https://oncohematology.abvpress.ru/ongm/article/view/105hematopoietic stem cell transplantationjuvenile myelomonocytic leukemiatransplant-related mortalityrelapse
spellingShingle M. A. Maschan
L. A. Khachatryan
Yu. V. Skvortsova
E. E. Kurnikova
D. A. Shasheleva
V. O. Bobrynina
D. N. Balashov
E. V. Skorobogatova
D. D. Baydildina
G. A. Novichkova
A. A. Maschan
Hematopoietic stem cell transplantation in juvenile myelomonocytic leukemia: analyse one centre experience and literature review
Онкогематология
hematopoietic stem cell transplantation
juvenile myelomonocytic leukemia
transplant-related mortality
relapse
title Hematopoietic stem cell transplantation in juvenile myelomonocytic leukemia: analyse one centre experience and literature review
title_full Hematopoietic stem cell transplantation in juvenile myelomonocytic leukemia: analyse one centre experience and literature review
title_fullStr Hematopoietic stem cell transplantation in juvenile myelomonocytic leukemia: analyse one centre experience and literature review
title_full_unstemmed Hematopoietic stem cell transplantation in juvenile myelomonocytic leukemia: analyse one centre experience and literature review
title_short Hematopoietic stem cell transplantation in juvenile myelomonocytic leukemia: analyse one centre experience and literature review
title_sort hematopoietic stem cell transplantation in juvenile myelomonocytic leukemia analyse one centre experience and literature review
topic hematopoietic stem cell transplantation
juvenile myelomonocytic leukemia
transplant-related mortality
relapse
url https://oncohematology.abvpress.ru/ongm/article/view/105
work_keys_str_mv AT mamaschan hematopoieticstemcelltransplantationinjuvenilemyelomonocyticleukemiaanalyseonecentreexperienceandliteraturereview
AT lakhachatryan hematopoieticstemcelltransplantationinjuvenilemyelomonocyticleukemiaanalyseonecentreexperienceandliteraturereview
AT yuvskvortsova hematopoieticstemcelltransplantationinjuvenilemyelomonocyticleukemiaanalyseonecentreexperienceandliteraturereview
AT eekurnikova hematopoieticstemcelltransplantationinjuvenilemyelomonocyticleukemiaanalyseonecentreexperienceandliteraturereview
AT dashasheleva hematopoieticstemcelltransplantationinjuvenilemyelomonocyticleukemiaanalyseonecentreexperienceandliteraturereview
AT vobobrynina hematopoieticstemcelltransplantationinjuvenilemyelomonocyticleukemiaanalyseonecentreexperienceandliteraturereview
AT dnbalashov hematopoieticstemcelltransplantationinjuvenilemyelomonocyticleukemiaanalyseonecentreexperienceandliteraturereview
AT evskorobogatova hematopoieticstemcelltransplantationinjuvenilemyelomonocyticleukemiaanalyseonecentreexperienceandliteraturereview
AT ddbaydildina hematopoieticstemcelltransplantationinjuvenilemyelomonocyticleukemiaanalyseonecentreexperienceandliteraturereview
AT ganovichkova hematopoieticstemcelltransplantationinjuvenilemyelomonocyticleukemiaanalyseonecentreexperienceandliteraturereview
AT aamaschan hematopoieticstemcelltransplantationinjuvenilemyelomonocyticleukemiaanalyseonecentreexperienceandliteraturereview